We are conducting a clinical research study evaluating an investigational medication, AZD8630, a
novel inhaled treatment designed to target inflammation and improve outcomes for people with severe
asthma.
novel inhaled treatment designed to target inflammation and improve outcomes for people with severe
asthma.
Who Can Join?
You may qualify if you:
- Are 18 to 75 years old
- Have a documented asthma diagnosis for at least 12 months
- Have experienced asthma exacerbations in the past year
- Have a blood eosinophil count ≥150/µL within 12 months
- Are currently taking inhaled corticosteroids (ICS) plus at least one additional controller medication
- (such as a long-acting beta-agonist [LABA])
Who Cannot Join?
You may not be eligible if you:
- Have a history of COPD, other chronic lung diseases, or significant smoking history
- Recently received another investigational medication or biologic therapy
- Have serious uncontrolled medical conditions that could interfere with study participation
About the Study Medication
AZD8630 is an inhaled investigational anti-inflammatory therapy being tested to determine if it can
reduce asthma symptoms, improve breathing, and prevent severe attacks.
reduce asthma symptoms, improve breathing, and prevent severe attacks.
Concomitant Medications Required
Participants must continue their current asthma regimen, which includes high-dose ICS plus additional
controllers (e.g., LABA, LAMA, leukotriene receptor antagonists, or theophylline, as prescribed).
Rescue medication (albuterol/salbutamol) use is also allowed.
controllers (e.g., LABA, LAMA, leukotriene receptor antagonists, or theophylline, as prescribed).
Rescue medication (albuterol/salbutamol) use is also allowed.
